Hofseth BioCare Q2 FY26 EBIT loss narrows to NOK 12.9 million; revenue falls 3.95% to NOK 65.7 million

Reuters2026/08/21 06:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Hofseth BioCare Q2 2026 revenue slipped 3.95% to NOK 65.7 million.
EBITDA loss narrowed to NOK 2.7 million from NOK 5.4 million a year earlier.
EBIT loss improved to NOK 12.9 million from NOK 14.9 million a year earlier.
Cash climbed NOK 59.7 million to NOK 108 million; total liquidity was NOK 109 million including available credit facilities.
Private placement raised gross NOK 144.5 million, including NOK 73.2 million via receivables conversion, settling across Q2–Q3.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hofseth BioCare ASA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608210215OMX_____CNEWS_EN_GNW1001258602_en) on August 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Hofseth BioCare Q2 FY26 EBIT loss narrows to NOK 12.9 million; revenue falls 3.95% to NOK 65.7 million

You may also like

Crypto prices